On Thursday, H.C. Wainwright initiated coverage on Alumis Inc (NASDAQ: ALMS), a clinical-stage biopharmaceutical company, with a Buy rating and a 12-month price target of $30.00. The firm highlighted the company's lead molecule, ESK-001, which is currently in Phase 3 development for the treatment of moderate-to-severe plaque psoriasis and in Phase 2 for systemic lupus erythematosus.
Alumis's ESK-001 has been recognized for its high selectivity in inhibiting Tyrosine Kinase 2 (TYK2), a target for treating immune-mediated diseases. According to the analyst, ESK-001 surpasses the efficacy of currently available treatments in the TYK2 inhibitor market, including Bristol Myers (NYSE:BMY) Squibb's Sotyktu (deucravacitinib) and Takeda's Phase 3 candidate TAK-279, neither of which were rated by the firm.
The coverage initiation follows the assessment of clinical data that suggests ESK-001 has a superior profile compared to Sotyktu, which currently leads the market for TYK2 inhibitors. The analyst expressed confidence in the potential market growth that ESK-001 could drive due to its efficacy, indicating that it could significantly expand the market share for the TYK2 class in treating large indications.
The firm's positive outlook on Alumis is also supported by the commercial success of Sotyktu, which the analyst notes as a factor that risk-mitigates the investment in Alumis. With the clinical data backing ESK-001's profile, the analyst believes that Alumis's lead molecule could catalyze the growth of the entire TYK2 market.
In other recent news, Alumis Inc. has made notable strides in its clinical trials and financial endeavors. The biopharmaceutical firm has reported positive interim results from a Phase 2 trial of ESK-001, its investigational oral treatment for moderate-to-severe plaque psoriasis. The company has also initiated patient dosing in its ONWARD Phase 3 clinical program for the same drug.
Alumis has received positive coverage from Cantor Fitzgerald and Morgan Stanley (NYSE:MS), both of which initiated coverage with an Overweight rating and highlighted the promising potential of the company's immunology pipeline. Both firms projected potential revenues exceeding $1 billion from drug candidates ESK-001 and A-005.
Furthermore, Alumis secured $40 million through a private placement of common stock, a move set to further the company's initiatives in the pharmaceutical preparations sector.
InvestingPro Insights
To complement the positive outlook presented by H.C. Wainwright on Alumis Inc (NASDAQ: ALMS), recent data from InvestingPro provides additional context for investors. Despite the promising potential of ESK-001, InvestingPro Tips reveal that Alumis is currently "quickly burning through cash" and is "not profitable over the last twelve months." This aligns with the company's status as a clinical-stage biopharmaceutical firm investing heavily in research and development.
The market seems to be recognizing Alumis's potential, as evidenced by a "significant return over the last week," with InvestingPro Data showing a 1-week price total return of 8.75%. However, the company's market capitalization stands at $608.77 million, reflecting the speculative nature of its valuation based on future prospects rather than current financials.
Interestingly, while H.C. Wainwright set a price target of $30.00, InvestingPro's fair value estimate is considerably lower at $9.01, suggesting a more conservative valuation based on current financials. This discrepancy highlights the importance of considering both the potential of Alumis's pipeline and its current financial position.
For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips for Alumis, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.